H.C. Wainwright Remains a Buy on Medical Transcription Billing (MTBC)


In a report released today, Kevin Dede from H.C. Wainwright reiterated a Buy rating on Medical Transcription Billing (NASDAQ: MTBC), with a price target of $6. The company’s shares closed on Friday at $4.39.

According to TipRanks.com, Dede ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -10.5% and a 34.4% success rate. Dede covers the Consumer Goods sector, focusing on stocks such as Top Image Systems, Microvision, and SuperCom.

Currently, the analyst consensus on Medical Transcription Billing is a Moderate Buy with an average price target of $6.

See today’s analyst top recommended stocks >>

The company has a one-year high of $5.44 and a one-year low of $1.32. Currently, Medical Transcription Billing has an average volume of 224.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Medical Transcription Billing Corp. is a healthcare information technology company, which engages in the provision of integrated suite of proprietary web-based solutions. Its products and services include electronic health records, practice management, patient engagement, medical billing, value added, consultancy, medical transcription, and business intelligence. The company was founded by Mahmud Ul Haq on September 28, 2001 and is headquartered in Somerset, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts